Less Invasive CABG Facilitated By St. Jude Connector Devices, Firm Believes
This article was originally published in The Gray Sheet
Executive Summary
The long-term reliability of St. Jude Medical's sutureless anastomotic Connector devices could shift the coronary therapy market away from stents and toward bypass surgery (CABG), the company suggested during a May 1 investor conference.
You may also be interested in...
Symmetry CABG Connector Leads St. Jude Cardiac Surgery Unit Growth
The rapid market adoption of the Symmetry sutureless aortic connector device for coronary bypass surgery (CABG) has offset declining sales of St. Jude's mechanical heart valve line, the company reported during its Jan. 30 quarterly conference call
Symmetry CABG Connector Leads St. Jude Cardiac Surgery Unit Growth
The rapid market adoption of the Symmetry sutureless aortic connector device for coronary bypass surgery (CABG) has offset declining sales of St. Jude's mechanical heart valve line, the company reported during its Jan. 30 quarterly conference call
St. Jude Vascular Closure Business Continues To Top 50% Sales Growth
Widespread acceptance of femoral artery closure devices pushed second-quarter sales of St. Jude Medical's Angio-Seal vascular closure device 52% versus the year-ago period, driving the firm's overall second-quarter earnings by almost 12% to $336 mil.